20.09.2016 | Erratum
Erratum to: Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature
Erschienen in: Immunologic Research | Ausgabe 1/2017
Einloggen, um Zugang zu erhaltenExcerpt
The original version of this article unfortunately contained a mistake. It has been corrected with this erratum. And the original article was also corrected.
After first dose
|
After second dose
|
After third dose
|
|
---|---|---|---|
Symptoms (within 5 days post-vaccination)
|
|||
Injection site reactions
|
|||
Pain
|
2
|
2
|
1
|
Uncontrollable and involuntary movement of the limb
|
1
|
||
Swelling
|
1
|
1
|
|
Systemic reactions
|
|||
Low-grade fever
|
3
|
5
|
1
|
Headache
|
5
|
5
|
2
|
Recurrent syncope
|
4
|
3
|
|
Persistent convulsive hunger
|
1
|
||
Irritability
|
1
|
2
|
|
Epileptic seizures
|
1
|
||
Temporary speech loss
|
1
|
||
Lower limbs paraesthesia and paresis
|
1
|
||
Hot flushes
|
1
|
||
Severe stomach pain
|
2
|
1
|
1
|
Insomnia
|
3
|
2
|
|
Hypersensitivity reactions
|
1
|
||
Leg muscle pain (myalgia)
|
1
|
3
|
1
|
Gait and orthostatic posture impairment
|
1
|
||
Excessive sweating
|
1
|
||
Vomiting
|
1
|
||
Symptoms (5–15 days post-vaccination)
|
|||
Systemic reactions
|
|||
Asthenia
|
2
|
5
|
1
|
Persistent thirst
|
3
|
||
Severe hands and feet itching
|
1
|
||
Optic neuritis
|
1
|
||
Symptoms (15–20 days post-vaccination)
|
|||
Systemic reactions
|
|||
Amenorrhoea
|
1
|
||
Skin rashes
|
1
|
1
|
|
Tachycardia
|
1
|
1
|
|
Difficult breathing
|
1
|
||
Weight loss
|
1
|
Major criteria
|
Previous exposure to an external stimulus (i.e. vaccine, adjuvant, silicone, nucleic acids, fragments of bacterial cell walls)
|
One of the following “typical” manifestations:
|
Myalgia/myositis, muscle weakness
|
Arthralgia and/or arthritis
|
Chronic fatigue, non-refreshing sleep or sleep disturbances
|
Neurological manifestations (especially if associated with demyelination)
|
Memory loss and cognitive impairment
|
Fever
|
Dry mouth
|
Improvement of symptoms after the removal of the triggering agent
|
Typical biopsy of the involved organs
|
Minor criteria
|
Appearance of autoantibodies or autoantibodies directed against the suspected adjuvant
|
Other clinical manifestations (i.e. functional somatic syndromes)
|
Association with specific HLA haplotypes (i.e. HLA-DRB1, HLA-DQB1)
|
Development of autoimmune diseases
|
Diagnostic requirements:
|
Two major criteria
|
One major criteria + two minor criteria
|